Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Trial ID or NCT#

NCT04729608

Status

not recruiting iconNOT RECRUITING

Purpose

This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.

Official Title

A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Eligibility Criteria

Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Jonathan S Berek
Jonathan S Berek
Gynecologic oncologist
Laurie Kraus Lacob Professor

Contact us to find out if this trial is right for you.

Contact

Bela Shah
650-723-0594

View on ClinicalTrials.gov